| meta-analysis | Q815382 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Roberto Bolli | Q56166630 |
| Marcin Wysoczynski | Q92128001 | ||
| P2093 | author name string | Abdur Rahman Khan | |
| Talha A Farid | |||
| Avnish Tripathi | |||
| Shahab Ghafghazi | |||
| Asif Pathan | |||
| P2860 | cites work | Transmyocardial laser revascularization versus medical therapy for refractory angina | Q24187921 |
| Enhanced external counterpulsation for chronic angina pectoris | Q24239959 | ||
| Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions | Q27001159 | ||
| Immunobiology of mesenchymal stem cells | Q27004487 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Direct myocardial revascularization and angiogenesis--how many patients might be eligible? | Q33873652 | ||
| Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. | Q34113038 | ||
| Endothelial progenitor cells: mobilization, differentiation, and homing | Q35114634 | ||
| Predictors of long-term clinical endpoints in patients with refractory angina | Q35135665 | ||
| Intramyocardial, autologous CD34+ cell therapy for refractory angina | Q35308043 | ||
| Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial | Q36694346 | ||
| Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies | Q37092349 | ||
| Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues | Q37092351 | ||
| Human studies of angiogenic gene therapy | Q37406656 | ||
| Treatment of refractory angina in patients not suitable for revascularization | Q38173640 | ||
| Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial | Q38381605 | ||
| Long-term survival in patients with refractory angina | Q39227491 | ||
| Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines | Q39639358 | ||
| Intracoronary autologous CD34+ stem cell therapy for intractable angina | Q42848065 | ||
| Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study | Q43497604 | ||
| Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials | Q44493479 | ||
| Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms | Q47248012 | ||
| Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms | Q47945142 | ||
| Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up | Q48459462 | ||
| Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction | Q48619654 | ||
| A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). | Q48657008 | ||
| Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. | Q50981942 | ||
| Selected CD133⁺ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial. | Q53050821 | ||
| Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. | Q53170753 | ||
| Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). | Q53455003 | ||
| Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction | Q74288420 | ||
| CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells | Q79317344 | ||
| P433 | issue | 6 | |
| P921 | main subject | circulatory system | Q11068 |
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 984-993 | |
| P577 | publication date | 2016-01-13 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis | |
| P478 | volume | 118 |
| Q27330396 | A New Method to Stabilize C-Kit Expression in Reparative Cardiac Mesenchymal Cells |
| Q88384212 | A comprehensive meta-analysis of stem cell therapy for chronic angina |
| Q40535232 | A prospective study of patients with refractory angina: outcomes and the role of high-sensitivity troponin T. |
| Q47190217 | Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials |
| Q36127860 | Biomaterial strategies to improve the efficacy of bone marrow cell therapy for myocardial infarction |
| Q55085484 | Cardiac Progenitor Cells in Basic Biology and Regenerative Medicine. |
| Q90082403 | Cardiac regenerative therapy: Many paths to repair |
| Q53508391 | Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials. |
| Q42343993 | Cell Therapy Augments Myocardial Perfusion and Improves Quality of Life in Patients With Refractory Angina. |
| Q48155875 | Cell Therapy for Refractory Angina: A Reappraisal. |
| Q89433729 | Introduction to a Compendium on Regenerative Cardiology |
| Q58741622 | Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133 cells in ischemic refractory cardiomyopathy trial (RECARDIO) |
| Q92218851 | Management of Refractory Angina Pectoris |
| Q55649548 | Midterm outcomes of transmyocardial laser revascularization with intramyocardial injection of adipose derived stromal cells for severe refractory angina. |
| Q57495833 | New Advances in the Management of Refractory Angina Pectoris |
| Q92356186 | Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine |
| Q49288386 | Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease. |
| Q30239945 | Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. |
| Q52778918 | Stem cells: Cell therapy for cardiac repair: what is needed to move forward? |
| Q46102792 | The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. |
| Q41279938 | The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction |
| Q57494730 | The use of stem cells in ischemic heart disease treatment |
| Q89890431 | Time to end the war on cell therapy |
| Q49875736 | Transplantation of Allogeneic Pericytes Improves Myocardial Vascularization and Reduces Interstitial Fibrosis in a Swine Model of Reperfused Acute Myocardial Infarction. |
| Q47131900 | c-kit Positive Cardiac Outgrowth Cells Demonstrate Better Ability for Cardiac Recovery Against Ischemic Myopathy |
Search more.